{"text": "TITLE:\n      Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)\nSUMMARY:\n      The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor\n      Blocker, on top of the conventional treatment in high risk patients in Japan with\n      hypertension in terms of the morbidity and mortality.\nDETAILED DESCRIPTION:\n      Although many reports show that ACE inhibitors and angiotensin II receptor blockers (ARB)\n      are superior for prevention of cardiovascular events, previous data are not enough for the\n      patients who have more than one risk factor and for anti-atherosclerotic effects of ARB. In\n      Japan, there were only a few large-scale trials for cardiovascular disease prevention, and\n      it has not been clarified whether the evidence in Western countries could be unqualifiedly\n      applied to Japanese patients as a long-range strategy. The KYOTO HEART Study is to assess\n      the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional\n      treatment in high risk patients with hypertension in terms of the morbidity and mortality.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Clinical diagnosis of hypertension\n          -  Clinical diagnosis of one or more risk factors, such as diabetes, smoking habit,\n             lipid metabolism abnormality, history of ischemic heart disease (IHD) or\n             cerebrovascular disease, obesity (BMI>25), chronic heart failure (NYHA II-III), and\n             electrocardiogram (ECG) abnormality (LVH)\n        Exclusion Criteria:\n          -  Patients who have already been administered ARB\n          -  Patients with IHD within 6 months after percutaneous coronary intervention(PCI), and\n             who are stable but are going to implement PCI or coronary artery bypass\n             grafting(CABG)\n          -  Severe/malignant/secondary hypertensive patients\n          -  Pregnant women and women of childbearing potential\n          -  History of heart failure, unstable angina, myocardial infarction, PTCA, or CABG\n             within the preceding 6 months\n          -  Arrhythmia needed to be treated or accompanied with symptoms, second or third degree\n             AV block\n          -  Severe renal impairment (Serum creatinine >3.0 mg/dl)\n          -  Severe hepatic impairment (Hepatic failure, Cirrhosis, etc.)\n", "cuis": "C0216784 C0018787 C0947630 C1552616 C1706244 C0003018 C0523498 C0003009 C0373546 C0216784 C0018787 C0947630 C2945704 C0020538 C1963138 C1696708 C2748577 C0947663 C0220880 C0678257 C0033080 C1521941 C0003015 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C0684224 C0700287 C1979715 C1320716 C0199176 C3245479 C0455624 C1553898 C0007222 C0455539 C0348668 C1290379 C0455404 C0558373 C0849932 C0264656 C0042373 C0199176 C0175659 C0349674 C0237849 C0684254 C0679199 C0018787 C0947630 C2702329 C0003018 C0523498 C0003009 C0373546 C0216784 C2936586 C3850102 C0020538 C1963138 C1696708 C2748577 C0947663 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0220880 C0243161 C0013893 C0243161 C0020538 C1963138 C1696708 C2748577 C0947663 C0011900 C0945731 C0551521 C0552426 C0560182 C0686906 C0679838 C3272565 C0455624 C1553898 C4036105 C0455939 C0011900 C0945731 C0551521 C0552426 C0560182 C0686906 C0679838 C3272565 C0011849 C0011860 C0011847 C2242848 C0151744 C1313980 C0010054 C1510446 C0264694 C0025519 C3822292 C0262926 C2004062 C1704258 C3809765 C0523744 C0007820 C0585890 C0393949 C0810006 C0553766 C0393950 C0264716 C0018802 C0028754 C0013798 C1623258 C1705651 C0180600 C0877038 C2216046 C0278336 C0849142 C2215949 C0149721 C1704258 C3809765 C0243161 C1550655 C1578485 C1578486 C2360836 C2360838 C2360840 C0018787 C0151744 C1550655 C1578485 C1578486 C2360836 C2360838 C2360840 C1561542 C0886296 C1948041 C0010055 C1260596 C0371563 C0857121 C0947663 C0003364 C0027627 C1547227 C1547231 C1561581 C4050465 C4050466 C0264097 C0032927 C0549206 C2222792 C0455531 C2317056 C0027051 C2926063 C0155668 C0428953 C0264708 C0155626 C1273976 C0746727 C2348362 C1168331 C0455406 C0340324 C1998297 C0340312 C0340325 C0428950 C2825159 C0002965 C0340288 C2936173 C1561542 C0003811 C1457887 C0542560 C0332155 C0004245 C1565489 C1565662 C0201976 C0600061 C0858112 C0428282 C1547227 C1547231 C1561581 C4050465 C4050466 C0264097 C0948807 C0085605 C0023890 C1623038 C1547227 C1547231 C1561581 C4050465 C4050466 C0264097 ", "concepts": "Valsartan, heart, Study summary, summary Angiotensin, Angiotensin I, Angiotensin 2, Angiotensin II, valsartan, heart, Study conventional treatment hypertension, Hypertension, Prehypertensions, No hypertension, hypertensin, morbidity description, prescription, prescription ACE inhibitors, angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, report, report, H2 receptor blockers cardiovascular events, prevention, data risk factors, risk factors CVD - cardiovascular disease, H/O: cardiovascular disease, Cardiovascular disease other, Acute cardiovascular disease, FH: Cardiovascular disease, Preg.+ cardiovascular disease, fear of cardiovascular disease, cardiovascular renal disease, vascular disease, prevention, scales, scale, scales, scaler strategy, heart, Study, Orange Angiotensin, Angiotensin I, Angiotensin 2, Angiotensin II, valsartan, ADP Receptor Blockers, CCR5 Receptor Blockers hypertension, Hypertension, Prehypertensions, No hypertension, hypertensin, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, morbidity criteria, Eligibility Criteria hypertension, Hypertension, Prehypertensions, No hypertension, hypertensin, diagnosis, Diagnosis, ED diagnosis, ED diagnosis, no diagnosis, No diagnosis, Misdiagnosis, Clinical risk factors, risk factors, No risk factors, A/N risk factors, diagnosis, Diagnosis, ED diagnosis, ED diagnosis, no diagnosis, No diagnosis, Misdiagnosis, Clinical, Diabetes, diabetes, Diabetes, habits ihd, FH: Ischemic heart disease, ischaemic heart disease, Acute ischemic heart disease, Chronic ischemic heart disease, metabolism, H2 metabolism, history, history, Abnormality, No abnormality, lipids CVD - Cerebrovascular disease, H/O: cerebrovascular disease, Other cerebrovascular diseases, Acute cerebrovascular disease, Diffuse cerebrovascular disease, Other cerebrovascular disease OS, Chronic heart failure, Chronic heart failure, obesity electrocardiography, Electrocardiograph, Electrocardiogram, electrocardiographs, electrocardiogram PRWP, electrocardiogram PSVT, Fetal electrocardiogram, electrocardiogram (ECG), electrocardiogram: axis, lvh, Abnormality, No abnormality Criteria Patient, Patient, Patient, Patient, Patient, Patient coronary, ihd, Patient, Patient, Patient, Patient, Patient, Patient, month, intervention, intervention Coronary artery bypass graft, coronary artery graft bypass, Coronary artery bypass/reop hypertensive, hypertensin, Antihypertensive, secondary, Severe, Severe, Severe, Severe, Severe, Sever, premalignant Pregnant, OT potential History of heart failure, Family history of heart failure, Myocardial infarction, NOS, Myocardial infarction, Healed myocardial infarction, ECG: myocardial infarction, atrial myocardial infarction, Acute myocardial infarction, First myocardial infarction, septal myocardial infarction, Septal myocardial infarction, Apical myocardial infarction, FH: Myocardial infarction, Silent myocardial infarction, Recent myocardial infarction, Lateral myocardial infarction, Aborted myocardial infarction, ECG: no myocardial infarction, Date of myocardial infarction, unstable angina, stable angina, ptca month Arrhythmia, symptoms, degree, untreated AV block renal impairment, Acute renal impairment, Serum creatinine NOS, Serum creatinine level, Serum creatine, Serum creatinine low, Severe, Severe, Severe, Severe, Severe, Sever hepatic impairment, Hepatic failure, cirrhosis, Cirrhosis, Severe, Severe, Severe, Severe, Severe, Sever "}
